Physician profile
Naeem Sarfraz
NPI 1760427033
$31,262.79
in general payments reported to CMS, 2019-2025
74 companies · $4,778 in 2025
The $4,778 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,121 · 2020: $3,738 · 2021: $5,501 · 2022: $4,996 · 2023: $5,189 · 2024: $4,940 · 2025: $4,778.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,721.83 |
| Education | $184.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,815.48 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals Lp | $3,152.97 | 2019-2025 | Breztri, Farxiga, Fasenra |
| Glaxosmithkline, LLC. | $2,361.60 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,996.53 | 2019-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $1,479.87 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $1,282.61 | 2019-2025 | |
| Novo Nordisk INC | $1,158.63 | 2019-2024 | Ozempic, Rybelsus |
| Bausch Health US, LLC | $1,153.86 | 2020-2025 | Aplenzin, Wellbutrin |
| Amgen INC. | $1,030.46 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,029.78 | 2019-2025 | Jardiance, Ofev, Synjardy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $770.16 | 2022-2024 | Caplyta |
| Sunovion Pharmaceuticals INC. | $747.97 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $726.23 | 2019-2025 | Verquvo, Gardasil 9, Belsomra |
| Lilly USA, LLC | $633.93 | 2019-2025 | Jardiance, Emgality, Mounjaro |
| Sumitomo Pharma America, INC. | $574.92 | 2023-2025 | Gemtesa |
Show all 74 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naeem Sarfraz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.